Document is current
Any future updates will be listed below
-
Authors
Chen, Shang-Hung
Tsai, Hsiang-Lin
Jiang, Jeng-Kai
Sung, Yung-Chuan
Huang, Ching-Wen
Yeh, Yu-Min
Chen, Li-Tzong
Wang, Jaw-Yuan https://orcid.org/0000-0002-7705-2621
-
Funding
Funding for this research was provided by:
Merck Ltd.
Academia Sinica
Kaohsiung Medical University (KMUH107-7R28, KMUH107-7R29, KMUH107-7R30, KMUH107-7M22, KMUH107-7M23, KMUHS10701, KMUHS10706, KMUHS10710)
Ministry of Science and Technology (MOST108-2321-B-037-001, MOST107-2321-B-037-003, MOST107-2314-B-037-116, MOST107-2314-B-037-022-MY2, MOST107-2314-B-037-023-MY2)
Ministry of Health and Welfare (MOHW107-TDU-B-212-123006, MOHW107-TDU-B-212-114026B, MOHW108-TDU-B-212-133006, MOHW108-TDU-B-212-124026)
- License Information
-
More Information
Article History
Received: 30 May 2018
Accepted: 12 June 2019
First Online: 28 June 2019
Ethics approval and consent to participate
: This study will recruit 120 patients with mCRC from four medical institutions in Taiwan (Kaohsiung Medical University Chung-Ho Memorial Hospital, Taipei Veterans General Hospital, Cathay General Hospital, and National Cheng Kung University Hospital). The study has been approved by the ethics committee of the National Health Research Institutes (reference number: EC1060904), Kaohsiung Medical University Hospital (reference number: KMUHIRB-GII-20170027), Taipei Veterans General Hospital (reference number: 2017–12-003A), Cathay General Hospital (reference number: CGH-P107013), and National Cheng Kung University Hospital (reference number: A-BR-106-045). Written informed consent will be obtained from all patients before participation in this study.
: Not applicable.
: The authors declare that they have no competing interests.
